HLA-B27 antigen frequency among suspected Spondyloarthropathy patients attaining a tertiary level hospital of Bangladesh

Nessa, Afzalun; Tabassum, Shahina; Sultana, Shahzabeen

doi:10.3329/bmrcb.v40i3.25231

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean AS prevalence per 10,000 is estimated to be 23.8 in Europe. However, it is substantially lower in the Japanese population (0.7), consistent with the lower frequency of HLA-B27 in the Japanese general population (0.5% or less), compared with Europeans (4-13%) and other Asian populations such as the Chinese (4-8%) or South Koreans (2.3-3%) [5][6][7][8][9].…”

Section: Introductionsupporting

confidence: 53%

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

Kishimoto

Taniguchi

Fujishige

et al. 2019

Modern Rheumatology

View full text Add to dashboard Cite

Objective: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin-17A, improved the signs and symptoms of ankylosing spondylitis (AS) in three Phase 3 global studies (MEASURE 1, 2, and 3). Here, we describe the efficacy and safety results through Week 24 of a study of secukinumab in Japanese patients with active AS. Methods: In this multicenter, open-label, single arm, 52-week study, 30 AS patients self-administered secukinumab 150 mg subcutaneously at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter. The primary efficacy endpoint was ASAS 20 response at Week 16. Overall safety and tolerability were assessed beyond Week 24 up to the data reporting cutoff date. Results: The ASAS 20 response rate was 70% (21/30) at Week 16, which was sustained to Week 24. Secukinumab was effective in various clinical outcomes including patient's global assessment of disease activity, spinal pain, nocturnal pain, physical function, spinal mobility, and CRP level. Comparable ASAS 20 and 40 responses were observed regardless of previous anti-TNF therapy. Secukinumab was well-tolerated with a safety profile consistent with previous reports. Conclusion: Secukinumab 150 mg provided sustained improvement in the signs and symptoms of Japanese AS patients through 24 weeks, with no new or unexpected safety signals.

show abstract

Section: Introductionsupporting

confidence: 53%

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

Kishimoto

Taniguchi

Fujishige

et al. 2019

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…22,23 The specific genetic marker HLA-B27 was positive in 54% of Spondyloarthritis patients, with a men predominance. In a study conducted by Umamaheshwari et al, involving 50 patients, 26% of cases were found to be HLA-B27 positive, 24 while in other studies by Mishra MN et al, 25 and Nessa et al, 26 the frequency of HLA-B27 antigen among SpA patients were 56% and 49.2% respectively with our study.…”

Section: Discussionsupporting

confidence: 53%

Association of Genetic Marker HLA-B27 with Spondyloarthritis In A Tertiary Care Centre In South India

Thulukanam¹,

Muthamilan²,

Leela³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Human leukocyte antigens (HLA) are gene products found in the major histocompatibility complex, aiding in differentiation of “self” from “non-self” antigens, and is crucial for the communication between immune cells of the human body. HLA-B27, in specific, has a strong interrelation with different types of Spondyloarthritis (SpA). The aim of this study is to study the frequency of HLA-B27 in suspected Spondyloarthritis patients presenting with axial and peripheral joint involvement, who attended our tertiary care centre from August-2017 to January-2021. Patients fulfilling Assessment of Spondyloarthritis International Society (ASAS) criteria for Spondyloarthritis were included in the study, and were further classified into Spondyloarthritis sub-groups. Blood samples were collected for CRP and ESR tests along with HLA-B27 detection by RT-PCR method. Magnetic resonance imaging was done for sacroiliac joints in patients with lower back pain. Analysis of 289 samples of SpA patients revealed 156 (54%) to be HLA-B27 positive and 133 (46%) to be HLA-B27 negative. There were 98 patients (63%) with Ankylosing spondylitis, 33 (21%) had Reactive arthritis, 19 (12%) had Psoriatic arthritis, 6 (4%) had Undifferentiated Spondyloarthritis, and inflammatory bowel disease was diagnosed in 0% in HLA-B27 positive Spondyloarthritis patients. The frequency of HLA-B27 among the Spondyloarthritis (SpA) patients in our study was found to be 54% (156), more common clinical manifestation in men belonging to the age group of 16-25 years positive patients. Ankylosing spondylitis (AS) was found to be the most common sub-groups observed among the SpA patients.

show abstract

“…With a predominance of men, 54% of patients with spondyloarthritis tested positive for the particular genetic marker HLA-B27. HLA-B27 positivity was noticed in 26% of the 50 patients studied by Uma Maheshwari et al, 36 while additional investigations of Mishra MN et al 37 and Nessa et al 38 indicated that HLA-B27 antigen was present in 49.2% and 56% of SpA patients, respectively.…”

Section: Discussionmentioning

confidence: 91%

“…Comparing men and women with SpA patients, it was observed that more males (64%) than women (36%) had HLA-B27 positivity, which is consistent with other research findings. 36,38 However, Vaidya et al 3 stated that there was no significant difference was noticed in HLA-B27 incidence between women and men, and it was found that the illness was more common in the male population.…”

Section: Discussionmentioning

confidence: 99%

Correlation of Interleukin-17 and 23 Inflammatory Markers with Genetically Transmitted Spondyloarthritis Patients at a Tertiary Care Facility, South India

Thulukanam¹,

Leela²,

Venkatesan³

et al. 2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Human leukocyte antigens (HLA) are genetically derived proteins in the major histocompatibility complex. They help distinguish “self” and “non-self” antigens and are essential in interacting with the immune cells inside the body. The present research work examines the prevalence of HLA-B27 among patients suspected of Spondyloarthritis (SpA), which has also been correlated with Interleukin-17/23 Inflammatory Markers and other clinical manifestations and was carried out between August 2017 to January 2021. The patient’s blood samples were collected and tested for HLA-B27 and Interleukin-17/23 inflammatory markers. Among 289 SpA patients, 60% (172) were males, and 40% (117) were females, with a ratio of 1.5:1. Ankylosing Spondylitis (65.1%) was found to be the most prevalent subgroup of SpA among the patients, closely followed by reactive arthritis (21%), psoriatic arthritis (10.7%), undifferentiated spondyloarthritis (2.1%), and inflammatory bowel disease with associated arthritis (1%). HLA-B27 was found to be positive in 54% (156) out of 289 patients. Normal IL-17 ranges were seen in 42% of HLA-B27- positive patients, while increased IL-17 was seen in 58% of the population with positive HLA-B27 cases. IL-23 was found within normal ranges in 40% of positive HLA-B27 cases, while it was found to be increased in 60% of the positive HLA-B27 positive subjects. We concluded that HLA-B27 was found to be positive among more than half of the patient population with SpA. The early detection of HLA-B27 may aid in changing lifestyle to prevent Spondyloarthritides.

show abstract

HLA-B27 antigen frequency among suspected Spondyloarthropathy patients attaining a tertiary level hospital of Bangladesh

Cited by 4 publications

References 24 publications

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

Association of Genetic Marker HLA-B27 with Spondyloarthritis In A Tertiary Care Centre In South India

Correlation of Interleukin-17 and 23 Inflammatory Markers with Genetically Transmitted Spondyloarthritis Patients at a Tertiary Care Facility, South India

Contact Info

Product

Resources

About